IL99611A - Small stabilized ILOC .E plasmids - Google Patents
Small stabilized ILOC .E plasmidsInfo
- Publication number
- IL99611A IL99611A IL9961184A IL9961184A IL99611A IL 99611 A IL99611 A IL 99611A IL 9961184 A IL9961184 A IL 9961184A IL 9961184 A IL9961184 A IL 9961184A IL 99611 A IL99611 A IL 99611A
- Authority
- IL
- Israel
- Prior art keywords
- plasmid
- sequence
- gene
- dna
- plasmids
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims description 347
- 241000588724 Escherichia coli Species 0.000 title description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 209
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 58
- 230000010076 replication Effects 0.000 claims description 42
- 230000035897 transcription Effects 0.000 claims description 41
- 238000013518 transcription Methods 0.000 claims description 41
- 108020004999 messenger RNA Proteins 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 239000003550 marker Substances 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 24
- 108091008146 restriction endonucleases Proteins 0.000 claims description 16
- 108020004638 Circular DNA Proteins 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 238000012423 maintenance Methods 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 238000010188 recombinant method Methods 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 230000027086 plasmid maintenance Effects 0.000 claims description 8
- 230000009466 transformation Effects 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 description 96
- 239000012634 fragment Substances 0.000 description 66
- 239000000047 product Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 30
- 230000029087 digestion Effects 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 238000010276 construction Methods 0.000 description 24
- 238000010348 incorporation Methods 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 229930027917 kanamycin Natural products 0.000 description 14
- 229960000318 kanamycin Drugs 0.000 description 14
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 14
- 229930182823 kanamycin A Natural products 0.000 description 14
- 101800003838 Epidermal growth factor Proteins 0.000 description 12
- 102400001368 Epidermal growth factor Human genes 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241001515965 unidentified phage Species 0.000 description 12
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 12
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 102000013275 Somatomedins Human genes 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 230000000813 microbial effect Effects 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 description 8
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 210000003705 ribosome Anatomy 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000005030 transcription termination Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 101150107607 A4 gene Proteins 0.000 description 4
- 101150076489 B gene Proteins 0.000 description 4
- 241000761389 Copa Species 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000001124 posttranscriptional effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101150036540 Copb1 gene Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003578 bacterial chromosome Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000007849 functional defect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52196483A | 1983-08-10 | 1983-08-10 | |
| US06/636,727 US4710473A (en) | 1983-08-10 | 1984-08-06 | DNA plasmids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL99611A true IL99611A (en) | 1994-01-25 |
Family
ID=27060650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL72642A IL72642A (en) | 1983-08-10 | 1984-08-10 | Circular dna plasmid for use as transformation vector |
| IL9961184A IL99611A (en) | 1983-08-10 | 1984-08-10 | Small stabilized ILOC .E plasmids |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL72642A IL72642A (en) | 1983-08-10 | 1984-08-10 | Circular dna plasmid for use as transformation vector |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US4710473A (de) |
| EP (1) | EP0136490B1 (de) |
| JP (1) | JPH0797991B2 (de) |
| CA (1) | CA1312026C (de) |
| DE (1) | DE3481716D1 (de) |
| IL (2) | IL72642A (de) |
| WO (1) | WO1985000829A1 (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000831A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US5126252A (en) * | 1984-08-27 | 1992-06-30 | Bio-Technology General Corp. | Expressions vectors containing Lambda PL promoter and T1 T2 RNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and relatedmethods |
| US5081020A (en) * | 1984-08-27 | 1992-01-14 | Bio-Technology General Corp. | Expression vectors containing λPL promoter, T1 T2 rRNA termination sequence and origin of replication derived from a constitutive high copy number plasmid hosts and related methods |
| US5759816A (en) * | 1984-08-27 | 1998-06-02 | Bio-Technology General Corp. | Expression vectors containing λPL promoter and T1 T2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods |
| JP2594535B2 (ja) * | 1984-11-30 | 1997-03-26 | サントリー株式会社 | 高発現ベクターおよびその利用 |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
| US5110731A (en) * | 1985-08-26 | 1992-05-05 | Amgen, Inc. | System for biotin synthesis |
| US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
| WO1988006186A2 (en) * | 1987-02-19 | 1988-08-25 | The Upjohn Company | cDNAs ENCODING SOMATOTROPIN, EXPRESSION VECTORS AND HOSTS |
| US5240837A (en) * | 1987-02-19 | 1993-08-31 | The Upjohn Company | CDNAS encoding somatotropin, expression vectors and hosts |
| US5472702A (en) * | 1987-08-26 | 1995-12-05 | United States Surgical Corporation | Sterilization of growth factors |
| US5222978A (en) | 1987-08-26 | 1993-06-29 | United States Surgical Corporation | Packaged synthetic absorbable surgical elements |
| US5366081A (en) | 1987-08-26 | 1994-11-22 | United States Surgical Corporation | Packaged synthetic absorbable surgical elements |
| US4885252A (en) * | 1987-09-08 | 1989-12-05 | Eli Lilly And Company | Recombinant DNA expression vectors and DNA compounds that encode isopenicillin N synthetase from aspergillus nidulans |
| US5599690A (en) * | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
| US5714465A (en) * | 1989-05-19 | 1998-02-03 | Amgen Inc. | Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| US5359831A (en) | 1989-08-01 | 1994-11-01 | United States Surgical Corporation | Molded suture retainer |
| US5434135A (en) * | 1990-08-02 | 1995-07-18 | Indu Parikh | Growth factor compositions, preparation and use |
| IL99100A0 (en) * | 1990-08-13 | 1992-07-15 | Lilly Co Eli | Improved bacteriophage lambda pl promoters |
| CA2069741C (en) * | 1990-09-28 | 1996-06-18 | Kwang-Mu Yen | Cloning cartridges and expression vectors in gram-negative bacteria |
| CA2057715A1 (en) * | 1990-12-19 | 1992-06-20 | Charles L. Hershberger | Method for enhancing the structural stability of recombinant dna expression vectors |
| CA2059245C (en) * | 1991-02-08 | 2004-07-06 | Michael P. Chesterfield | Method and apparatus for calendering and coating/filling sutures |
| US5395761A (en) * | 1991-11-27 | 1995-03-07 | Eli Lilly And Company | Plasmid pHKY334, an expression vector for EK-BGH and host cells transformed therewith |
| IL107642A0 (en) * | 1992-11-20 | 1994-02-27 | Amgen Inc | Progenitor b cell stimulating factor |
| US5663304A (en) * | 1993-08-20 | 1997-09-02 | Genentech, Inc. | Refolding of misfolded insulin-like growth factor-I |
| US5407810A (en) * | 1993-08-20 | 1995-04-18 | Genentech, Inc. | Aqueous multiple-phase isolation of polypeptide |
| US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| US5446024A (en) * | 1993-12-17 | 1995-08-29 | Genentech, Inc. | Purification of insulin-like growth factor |
| US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US5904716A (en) * | 1995-04-26 | 1999-05-18 | Gendler; El | Method for reconstituting cartilage tissue using demineralized bone and product thereof |
| US20030207827A1 (en) * | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
| US20050147611A1 (en) * | 1995-12-22 | 2005-07-07 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US7632922B1 (en) * | 1995-12-22 | 2009-12-15 | Amgen, Inc. | Osteoprotegerin |
| AU718382B2 (en) * | 1996-11-08 | 2000-04-13 | Neose Technologies, Inc. | Improved expression vectors |
| TR199901734T2 (xx) * | 1996-11-15 | 2000-01-21 | Genentech, Inc. | N�rotrofinlerin ar�t�lmas�. |
| EP2371962A3 (de) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand für Rezeptor Aktivator von NF-KAPPA B, Ligand ist Mitglied der TNF Superfamilie |
| EP0911342B2 (de) * | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Neues protein und verfahren zu dessen herstellung |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| JP2001526532A (ja) | 1997-04-16 | 2001-12-18 | アムジエン・インコーポレーテツド | オステオプロテゲリン結合性蛋白および受容体 |
| US6265542B1 (en) | 1997-10-24 | 2001-07-24 | Genentech, Inc. | Purification of molecules |
| AU6788900A (en) * | 1999-09-03 | 2001-04-10 | Amgen, Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| KR100814313B1 (ko) * | 2000-04-06 | 2008-03-18 | 교와 핫꼬 고교 가부시끼가이샤 | 대장균의 염색체 재조합에 사용되는 플라스미드 |
| US6780405B1 (en) * | 2000-04-28 | 2004-08-24 | Avant Immunotherapeutics, Inc. | Regulated antigen delivery system (RADS) |
| CA2412277A1 (en) * | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Synthetic erythropoiesis stimulating proteins |
| ES2324645T3 (es) | 2000-11-03 | 2009-08-12 | Genentech, Inc. | Cambios de tasa metabolica en fermentaciones que expresen proteinas recombinantes. |
| IL158719A0 (en) | 2001-05-11 | 2004-05-12 | Amgen Inc | Peptides and related molecules that bind to tall-1 |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| AU2003243139B2 (en) | 2002-04-05 | 2007-06-21 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| EP1684791A4 (de) | 2003-10-27 | 2009-07-01 | Amgen Inc | Zusammensetzungen und verfahren zur modulierung einer immunantwort auf ein immunogenes therapeutisches mittel |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| ES2446416T3 (es) | 2005-12-09 | 2014-03-07 | Amgen, Inc. | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos |
| MY143274A (en) | 2005-12-22 | 2011-04-15 | Genentech Inc | Recombinant production of heparin binding proteins |
| SG162834A1 (en) | 2006-07-14 | 2010-07-29 | Genentech Inc | Refolding of recombinant proteins |
| ES2393326T3 (es) * | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| EP2111399A2 (de) * | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenon-verbindungen mit prolylhydroxylase-hemmungsaktivität sowie zusammensetzungen daraus und anwendungen davon |
| CA2683738C (en) * | 2007-04-18 | 2012-03-20 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| US8048894B2 (en) * | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| US8097620B2 (en) * | 2007-05-04 | 2012-01-17 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| CA2685216C (en) * | 2007-05-04 | 2014-07-08 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| US20090192554A1 (en) | 2008-01-29 | 2009-07-30 | Confluent Surgical, Inc. | Bioabsorbable block copolymer |
| US8748097B1 (en) | 2011-12-02 | 2014-06-10 | President And Fellows Of Harvard College | Identification of agents for treating calcium disorders and uses thereof |
| EP4168557A1 (de) * | 2020-06-17 | 2023-04-26 | Basf Se | Regulierung und integration der plasmidkopienzahl |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2759053A1 (de) * | 1977-12-30 | 1979-07-12 | Uhlin | Verfahren zum herstellen von genprodukten von plasmid-dns |
| FI793884A (fi) * | 1978-12-26 | 1980-06-27 | Cetus Corp | Stabila plasmider med stort kopieantal |
| US4374927A (en) * | 1981-02-24 | 1983-02-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Extrachromosomal regulation of expression |
| CA1198067A (en) * | 1981-02-27 | 1985-12-17 | David H. Gelfand | Stable high copy number plasmids |
| WO1983004030A1 (en) * | 1982-05-06 | 1983-11-24 | Applied Molecular Genetics, Inc. | The manufacture and expression of genes for urogastrone and polypeptide analogs thereof |
| JPH0753111B2 (ja) * | 1982-09-16 | 1995-06-07 | ベンツォン ファーマ エイ／エス | 条件非制御の複製挙動を持つプラスミド |
| CA1209501A (en) * | 1982-09-16 | 1986-08-12 | Nikos Panayotatos | Expression vector |
| DK410783D0 (da) * | 1982-09-16 | 1983-09-09 | Benzon A Salfred | Fremgangsmade til stabilisering af plasmider |
| WO1984001150A1 (en) * | 1982-09-16 | 1984-03-29 | Amgen | Avian growth hormones |
| NL8203716A (nl) * | 1982-09-24 | 1984-04-16 | Tno | Dna en plasmiden. |
| GB8308236D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
-
1984
- 1984-08-06 US US06/636,727 patent/US4710473A/en not_active Expired - Lifetime
- 1984-08-09 WO PCT/US1984/001251 patent/WO1985000829A1/en unknown
- 1984-08-09 JP JP59503110A patent/JPH0797991B2/ja not_active Expired - Lifetime
- 1984-08-10 EP EP84109538A patent/EP0136490B1/de not_active Expired
- 1984-08-10 DE DE8484109538T patent/DE3481716D1/de not_active Expired - Lifetime
- 1984-08-10 CA CA000460748A patent/CA1312026C/en not_active Expired - Lifetime
- 1984-08-10 IL IL72642A patent/IL72642A/xx not_active IP Right Cessation
- 1984-08-10 IL IL9961184A patent/IL99611A/en not_active IP Right Cessation
-
1994
- 1994-05-16 US US08/243,604 patent/US5674746A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL72642A0 (en) | 1984-11-30 |
| WO1985000829A1 (en) | 1985-02-28 |
| EP0136490A3 (en) | 1985-10-09 |
| JPS60501988A (ja) | 1985-11-21 |
| US5674746A (en) | 1997-10-07 |
| US4710473A (en) | 1987-12-01 |
| IL72642A (en) | 1993-04-04 |
| JPH0797991B2 (ja) | 1995-10-25 |
| EP0136490B1 (de) | 1990-03-21 |
| EP0136490A2 (de) | 1985-04-10 |
| DE3481716D1 (de) | 1990-04-26 |
| CA1312026C (en) | 1992-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0136490B1 (de) | DNS-Plasmide | |
| Brosius | Toxicity of an overproduced foreign gene product in Escherichia coli and its use in plasmid vectors for the selection of transcription terminators | |
| JP3375970B2 (ja) | ヘテロローガスなポリペプチドを分泌させるための方法および組成物 | |
| EP0136907A2 (de) | Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine | |
| US7264946B2 (en) | Thermoanaerobacter brockii alcohol dehydrogenase promoter for expression of heterologous proteins | |
| NO327325B1 (no) | Ekspresjonsvektor, vertcelle samt fremgangsmate for fremstilling av et peptidprodukt. | |
| EP0885967A2 (de) | Expressionsplasmide für Chaperon (Molekulärkappe) | |
| EP1019487A1 (de) | Expressionskontrollsequenzen | |
| JP2544602B2 (ja) | 新規プラスミドベクタ− | |
| US5437988A (en) | Expression and secretion of mature human beta interleukin-1 in Bacillus subtilis and means and methods for its achievement | |
| US5192669A (en) | Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences | |
| EP0685560A2 (de) | Methode zur Kontrolle genetischer Expressionen | |
| EP0130074B1 (de) | Übertragbare induzierbare Kontrollsysteme, diese enthaltende Expressionsvektoren, mit diesen transformierte Mikroorganismen und ihre Verwendung bei der Expression von exogenem Protein | |
| EP1307569B1 (de) | Herstellung eines rekombinanten proteins in prokaryotischen wirtszellen durch kodonsoptimisierung | |
| Haydon et al. | A mutation causing constitutive synthesis of the pyruvate dehydrogenase complex in Escherichia coli is located within the pdhR gene | |
| EP0179786B1 (de) | Expressionsvektoren mit hoher kopienanzahl | |
| JP2515488B2 (ja) | ポリペプチドの製造方法 | |
| US4912046A (en) | Portable inducible control system | |
| US5654169A (en) | Vectors and transformed host cells for recombinant protein production at reduced temperatures | |
| EP0215110B1 (de) | Herstellung menschlichen somatomedins c | |
| Warne et al. | Use of a modified Escherichia coli trpR gene to obtain tight regulation of high-copy-number expression vectors | |
| AU615432B2 (en) | Cdnas encoding somatotropin, expression vectors and hosts | |
| US5470721A (en) | Production of human somatomedin C | |
| EP0493926A1 (de) | Verfahren zur Erhöhung der strukturellen Stabilität von rekombinanten DNS-Expressionsvektoren | |
| JPH01160488A (ja) | ポリペプチド類を生産するための新規ベクターおよび発現配列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |